{"id":70770,"date":"2026-05-12T10:58:38","date_gmt":"2026-05-12T10:58:38","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70770"},"modified":"2026-10-15T10:33:58","modified_gmt":"2026-10-15T10:33:58","slug":"hgh-191aa","status":"publish","type":"product","link":"https:\/\/medsbase.com\/it\/product\/hgh-191aa\/","title":{"rendered":"HGH 191AA"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Risposta rapida \u2014 Cos'\u00e8 l'HGH 191AA?<\/h3>\n<p style=\"margin: 0;\"><strong>HGH 191AA<\/strong> is recombinant human growth hormone in its full 191-amino-acid native sequence form (somatropin), a 22-kDa pituitary peptide hormone produced by recombinant DNA technology to exactly match the endogenous human GH polypeptide. It acts directly on the growth hormone receptor (GHR) to activate JAK2\/STAT5 signalling and drive hepatic IGF-1 production. This is the modern pharmaceutical-quality form (191AA) as opposed to the obsolete bacterial 192AA recombinant variant. Supplied in 10\u201340\u00a0IU lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Cosa ottieni con MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/it\/reviews\/\">recensioni dei clienti<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Ogni ordine \u00e8 coperto dalla nostra <a href=\"https:\/\/medsbase.com\/it\/medsbase-re-shipment-assurance-policy\/\"><strong>Politica di Garanzia di Rispedizione<\/strong><\/a> \u2014 se il tuo pacco non arriva entro 20 giorni lavorativi, lo rispediamo.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Specifiche<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Dettaglio<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Numero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">12629-01-5 (somatropina) \/ 96827-07-5 (somatropina ricombinante)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Tipo<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Proteina ricombinante \u2014 sequenza nativa umana dell'ormone della crescita a 191 aminoacidi (somatropina); INN: somatropina<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Peso molecolare<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">22.124 Da (~22 kDa)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Struttura<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Catena polipeptidica singola di 191 amminoacidi ripiegata in una topologia canonica a quattro fasci elicoidali, stabilizzata da due ponti disolfuro intramolecolari (Cys53\u2013Cys165 e Cys182\u2013Cys189). La designazione 191AA distingue la forma moderna di qualit\u00e0 farmaceutica dalla variante batterica ricombinante obsoleta 192AA che presentava un metionina aggiuntiva all'estremit\u00e0 N-terminale.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Attivit\u00e0 Unitaria<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Circa 3 UI per mg di HGH ricombinante 191AA (unit\u00e0 internazionali, standard WHO)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Proteina ricombinante liofilizzata (polvere bianca o bianco sporco)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Purezza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226598% (verificato con HPLC, COA disponibile su richiesta)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Conservazione<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizzato: 2\u20138 \u00b0C (frigorifero) per lo stock di lavoro; \u221220 \u00b0C per lo stoccaggio a lungo termine di flaconcini non aperti. Ricostituito: 2\u20138 \u00b0C, utilizzare entro ~14 giorni. Proteggere dalla luce. Non congelare-scongelare la soluzione ricostituita \u2014 le proteine ricombinanti sono particolarmente sensibili alla denaturazione da congelamento-scongelamento.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilit\u00e0<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Acqua batteriostatica (consigliata). Proteina carrier (BSA, 0.1%) opzionale per diluizioni di lavoro per minimizzare le perdite per adsorbimento.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>Cos'\u00e8 l'HGH 191AA?<\/h2>\n<p><strong>HGH 191AA<\/strong> is recombinant human growth hormone (somatropin) in the 191-amino-acid native human sequence form. It is produced by recombinant DNA technology and matches the endogenous human GH polypeptide exactly \u2014 same 191 amino acids, same four-helix bundle three-dimensional structure, same two intramolecular disulfide bonds at Cys53\u2013Cys165 and Cys182\u2013Cys189. The 191AA designation specifically distinguishes the modern pharmaceutical-quality recombinant form from the older 192AA variant produced in bacterial expression systems, which carried an additional N-terminal methionine that introduced minor antigenicity differences and has been largely phased out of studies and clinical use. HGH is the principal peptide hormone secreted by somatotroph cells of the anterior pituitary in episodic pulses, with peak amplitudes occurring during early slow-wave sleep and following intense exercise. Endogenous secretion is regulated upstream by hypothalamic GHRH (positive) and somatostatin (negative). The recombinant 191AA form has empirical molecular weight 22,124\u00a0Da, INN somatropin, CAS number 12629-01-5 for the native protein and 96827-07-5 for the recombinant form. Standard unit activity for recombinant 191AA HGH is approximately 3\u00a0IU per mg according to the WHO International Standard. The compound is supplied as a high-purity lyophilized powder for reconstitution with bacteriostatic water. HGH is the most stringently regulated of all peptides in many jurisdictions and is approved for specific medical indications (paediatric GH deficiency, adult GH deficiency, Turner syndrome, idiopathic short stature, AIDS wasting, short bowel syndrome) only under prescription. For peptides that stimulate endogenous GH release rather than supplying exogenous GH, see our <a href=\"https:\/\/medsbase.com\/it\/sermorelin\/\">Sermorelin<\/a>, <a href=\"https:\/\/medsbase.com\/it\/cjc-1295-with-dac\/\">CJC-1295 con DAC<\/a>, e <a href=\"https:\/\/medsbase.com\/it\/ipamorelin\/\">Ipamorelin<\/a> Ci\u00f2 che differenzia il tirzepatide dai precedenti peptidi a incretina singola \u00e8 il suo. <\/p>\n<h2>Meccanismo d'Azione \u2014 Segnalazione del Recettore dell'Ormone della Crescita e l'Asse GH\/IGF<\/h2>\n<p>What makes HGH 191AA mechanistically distinctive among peptides is that it is the <strong>ligando esogeno diretto<\/strong> for the growth hormone receptor \u2014 not an analog, not a secretagogue, but the native polypeptide itself. The downstream signalling cascade has been characterised across decades of published studies:<\/p>\n<ul>\n<li><strong>Legame del recettore dell'ormone della crescita (GHR) e omodimerizzazione<\/strong> \u2014 L'HGH lega una singola molecola di GHR con alta affinit\u00e0 e induce l'omodimerizzazione con una seconda unit\u00e0 recettoriale, formando il complesso ligando-recettore bioattivo 1:2. Il recettore dimerizzato recluta la chinasi Janus 2 (JAK2) citoplasmatica al motivo box recettoriale intracellulare, portando alla trans-fosforilazione di JAK2 e del recettore stesso. Questo \u00e8 il meccanismo canonico di attivazione del recettore di citochine di Tipo I.<\/li>\n<li><strong>Attivazione del fattore di trascrizione JAK2\/STAT5<\/strong> \u2014 JAK2 fosforilata fosforila il Trasduttore di Segnale e Attivatore della Trascrizione 5 (STAT5), principalmente STAT5b, che poi dimerizza e si trasloca nel nucleo dove si lega ai promotori dei geni responsivi al GH. Il principale output trascrizionale \u00e8 l'induzione dell'espressione di IGF-1 (Fattore di Crescita Insulino-simile 1) negli epatociti \u2014 il principale effettore endocrino degli effetti periferici di promozione della crescita del GH. Altri geni responsivi al GH includono le proteine SOCS (feedback negativo), CIS e un programma di geni di sintesi proteica epatica.<\/li>\n<li><strong>Effetti tissutali diretti e indiretti (mediati da IGF-1)<\/strong> \u2014 Il GH ha due principali modalit\u00e0 di azione. <em>Effetti diretti<\/em>: lipolysis at adipocytes, glucose-counter-regulatory effects opposing insulin in muscle and liver, and direct anabolic signalling at GHR-expressing tissues including chondrocytes (in long-bone growth-plate studies) and immune cells. <em>Effetti indiretti tramite IGF-1<\/em>: hepatic IGF-1 acts at the IGF-1 receptor on essentially every cell type to drive Akt\/mTOR-mediated protein synthesis, cell proliferation, and survival signalling. The compound <a href=\"https:\/\/medsbase.com\/it\/igf-1-lr3\/\">IGF-1 LR3<\/a> \u00e8 lo strumento canonico diretto del recettore IGF utilizzato per distinguere gli effetti diretti del GH dagli effetti a valle mediati da IGF-1.<\/li>\n<\/ul>\n<p>HGH has a relatively short plasma half-life (~3\u20135 hours following subcutaneous administration of the native protein) due to renal filtration and proteolytic clearance. The pulsatile pattern of endogenous secretion is a defining feature of the GH axis \u2014 tonic continuous exposure to GH produces different downstream gene-expression patterns than pulsatile exposure, an important consideration in protocol design. Subcutaneous administration is the standard administration route. For endogenous-pulse-pattern studies, secretagogues like <a href=\"https:\/\/medsbase.com\/it\/sermorelin\/\">Sermorelin<\/a>, <a href=\"https:\/\/medsbase.com\/it\/cjc-1295-with-dac\/\">CJC-1295<\/a>, e <a href=\"https:\/\/medsbase.com\/it\/ipamorelin\/\">Ipamorelin<\/a> preservano la firma pulsatile naturale; per la farmacologia diretta del recettore GH, l'HGH esogeno fornisce lo stimolo pi\u00f9 pulito. <\/p>\n<h2>Published Evidence<\/h2>\n<p>HGH 191AA is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Farmacologia dell'asse dell'ormone della crescita<\/strong> \u2014 direct GHR signalling, JAK2\/STAT5 phosphorylation kinetics, downstream IGF-1 induction; canonical peptide for the GH side of the GH\/IGF-1 axis<\/li>\n<li><strong>IGF-1 induction studies<\/strong> \u2014 espressione genica epatica di IGF-1, dinamiche circolanti di IGF-1, regolazione delle proteine leganti IGF (IGFBP); comparatore per <a href=\"https:\/\/medsbase.com\/it\/igf-1-lr3\/\">IGF-1 LR3<\/a>-based studies that bypasses the GH step<\/li>\n<li><strong>Anabolic signalling studies<\/strong> \u2014 sintesi proteica del muscolo scheletrico via Akt\/mTOR (largamente mediata da IGF-1), segnalazione dei condrociti della piastra di crescita ossea, lipolisi del tessuto adiposo<\/li>\n<li><strong>Hepatic metabolism studies<\/strong> \u2014 produzione epatica di glucosio, metabolismo lipidico, risposta trascrizionale specifica degli epatociti alla stimolazione con GH<\/li>\n<li><strong>Modelli preclinici di deficienza di GH<\/strong> \u2014 studi di salvataggio in roditori ipofisectomizzati, modelli murini di nano Snell e nano Ames, caratterizzazione del knockout transgenico del GHR<\/li>\n<li><strong>Sleep and circadian rhythm support<\/strong> \u2014 relazione tra architettura del sonno e secrezione pulsatile di GH, dipendenza del GH dal sonno a onde lente<\/li>\n<li><strong>Comparative GH-axis studies<\/strong> \u2014 benchmarking rispetto agli analoghi del GHRH (<a href=\"https:\/\/medsbase.com\/it\/sermorelin\/\">Sermorelin<\/a>, <a href=\"https:\/\/medsbase.com\/it\/cjc-1295-with-dac\/\">CJC-1295<\/a>) e ai secretagoghi dell'ormone della crescita (<a href=\"https:\/\/medsbase.com\/it\/ipamorelin\/\">Ipamorelin<\/a>, <a href=\"https:\/\/medsbase.com\/it\/ghrp-6\/\">GHRP-6<\/a>, <a href=\"https:\/\/medsbase.com\/it\/ghrp-2\/\">GHRP-2<\/a>) che producono impulsi endogeni di GH piuttosto che la sostituzione esogena di GH<\/li>\n<li><strong>Tissue regeneration and wound healing studies<\/strong> \u2014 letteratura pubblicata sugli effetti del GH nei modelli di lesioni da ustione, recupero chirurgico e rigenerazione tissutale; relazione con <a href=\"https:\/\/medsbase.com\/it\/tb-500\/\">TB-500<\/a> e <a href=\"https:\/\/medsbase.com\/it\/bpc-157\/\">BPC-157<\/a> healing peptide studies<\/li>\n<li><strong>Endocrinology and aging studies<\/strong> \u2014 somatopause and age-related GH decline, comparative studies of GH replacement vs GH-axis stimulation in aging study models.<\/li>\n<\/ul>\n<p>Per un contesto pi\u00f9 ampio su dove si colloca l'HGH 191AA nel panorama dei peptidi dell'asse della crescita, vedere <a href=\"https:\/\/medsbase.com\/it\/sermorelin\/\">Sermorelin<\/a> e <a href=\"https:\/\/medsbase.com\/it\/cjc-1295-with-dac\/\">CJC-1295 con DAC<\/a> come comparatori dell'asse GHRH, <a href=\"https:\/\/medsbase.com\/it\/ipamorelin\/\">Ipamorelin<\/a> come comparatore selettivo del GHS, e <a href=\"https:\/\/medsbase.com\/it\/igf-1-lr3\/\">IGF-1 LR3<\/a> come agonista del recettore IGF a valle. Esplora l'intero <a href=\"https:\/\/medsbase.com\/it\/peptides\/\">catalogo peptidi<\/a> per composti correlati. <\/p>\n<h2>Concentrazioni e Dosaggi Disponibili<\/h2>\n<p>MedsBase stocks HGH 191AA in five lyophilized vial sizes calibrated by international units (IU). Each strength is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Concentrazione per flaconcino (UI)<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Massa approssimativa<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso d'Uso Tipico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Dimensioni della Confezione<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10 UI<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~3,3 mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Dosaggio pilota, titolazione a basso livello, protocolli a ciclo breve<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 fiale<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>15 UI<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~5 mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength, mid-titration arm<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 fiale<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>24 UI<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~8 mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Extended-cycle studies, higher-dose titration arm<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 fiale<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>36 IU<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~12 mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Protocolli plurisettimanali da un singolo flaconcino, volume di ricostituzione inferiore per dose<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 fiale<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>40 IU<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~13,3 mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Bulk packs vial, lowest per-IU cost, multi-cohort studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 fiale<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>All five strengths are the same chemical form (lyophilized recombinant 191AA somatropin, \u226598% HPLC purity). The IU labelling convention is the standard for HGH studies and clinical literature; the approximate mg equivalents are provided for users calibrating dose against mg-based literature. Higher-IU vials require smaller reconstitution volumes per unit dose, useful for minimising injection volume in rodent protocols or running extended-cycle studies from a single vial. <\/p>\n<h2>Confronto \u2014 HGH 191AA vs Sermorelin<\/h2>\n<p>HGH 191AA e <a href=\"https:\/\/medsbase.com\/it\/sermorelin\/\">Sermorelin<\/a> represent the two opposing pharmacological approaches to GH-axis studies: exogenous GH replacement vs endogenous GH stimulation. The comparison is one of the most-cited in growth-axis studies design because the two approaches answer different studies questions and produce qualitatively different downstream phenotypes. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Criterio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">HGH 191AA<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Sermorelin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Cos'\u00e8<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GH esogeno stesso (ricombinante)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Analogico GHRH(1-29) \u2014 stimola il GH endogeno<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Lunghezza<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">191 aminoacidi (~22 kDa)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">29 aminoacidi (~3 kDa)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Meccanismo d'azione<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Agonismo diretto del GHR (sostituzione)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Agonismo del recettore ipotalamico del GHRH (stimolazione)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Schema pulsatile del GH<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Esposizione tonica dopo ogni iniezione<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Pulsatile (preserva il ritmo naturale)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Feedback negativo<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Eluso (sopprime i somatotropi endogeni)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Preservato (la somatostatina rimane attiva)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Emivita plasmatica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~3\u20135 ore (SC)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~10\u201320 minuti (molto breve)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Uso clinico approvato<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Multiple indicazioni approvate (Genotropin, Humatrope, Norditropin, ecc.)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Approvazione storica della FDA per GHD pediatrico (Geref); discontinuato<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Dosaggio tipico<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">1\u20138 UI per somministrazione<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">100\u2013500 mcg per somministrazione<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For studies interested in direct GHR pharmacology, IGF-1 induction kinetics, or replacing GH in deficiency models, HGH 191AA is the canonical tool because it provides the exogenous ligand directly. For studies interested in physiological pulsatile GH dynamics, hypothalamic-pituitary-axis pharmacology, or any protocol where preserving the natural somatostatin feedback loop matters, <a href=\"https:\/\/medsbase.com\/it\/sermorelin\/\">Sermorelin<\/a> (e i correlati <a href=\"https:\/\/medsbase.com\/it\/cjc-1295-with-dac\/\">CJC-1295 con DAC<\/a>) provide the upstream-stimulation alternative. Many published studies designs use both in parallel arms to dissect direct GH effects from secretagogue-stimulated endogenous GH effects. <\/p>\n<h2>Conservazione e ricostituzione<\/h2>\n<p><strong>Prima della ricostituzione:<\/strong> conservare i flaconcini liofilizzati refrigerati a 2\u20138 \u00b0C nella confezione originale per lo stock di lavoro a breve termine. Per lo stoccaggio a lungo termine non aperto, congelare a \u221220 \u00b0C. L'HGH ricombinante liofilizzato \u00e8 stabile in refrigerazione fino a 24 mesi e a \u221220 \u00b0C fino a 36 mesi. Lo stato di ripiegamento a quattro eliche \u00e8 preservato nella forma liofilizzata. Evitare cicli di congelamento-scongelamento sulla polvere liofilizzata. <strong>Procedura di ricostituzione:<\/strong> iniettare acqua batteriostatica lungo la parete laterale del flaconcino (non direttamente sul panetto liofilizzato). I volumi di ricostituzione raccomandati variano in base alla concentrazione del flaconcino \u2014 per un flaconcino da 10 UI, 1,0 mL di acqua batteriostatica produce una concentrazione di lavoro di 10 UI\/mL; per un flaconcino da 36 UI, 1,5 mL produce 24 UI\/mL. Agitare delicatamente \u2014 non <strong>not<\/strong> scuotere \u2014 e attendere 5\u201310 minuti per la completa dissoluzione. Le proteine ricombinanti si dissolvono pi\u00f9 lentamente dei piccoli peptidi; non affrettare il passaggio di dissoluzione. L'agitazione vigorosa pu\u00f2 alterare la struttura a quattro eliche e ridurre l'attivit\u00e0. Una soluzione ricostituita correttamente dovrebbe essere limpida e incolore senza particelle visibili. <strong>Dopo la ricostituzione:<\/strong> conservare refrigerato a 2\u20138 \u00b0C e utilizzare entro 14 giorni per una stabilit\u00e0 ottimale \u2014 un periodo leggermente pi\u00f9 breve rispetto ai 30 giorni previsti per i peptidi sintetici pi\u00f9 piccoli perch\u00e9 la proteina a quattro eliche di maggiori dimensioni \u00e8 pi\u00f9 suscettibile a perdite per adsorbimento superficiale e lenta deamidazione. Non congelare la soluzione ricostituita \u2014 i cicli di congelamento-scongelamento producono aggregazione e perdita di attivit\u00e0 biologica. Scartare qualsiasi flaconcino che presenti torbidit\u00e0, precipitato o scolorimento. Per diluizioni di lavoro prolungate inferiori a 0,1 mg\/mL (~0,3 UI\/mL), la proteina carrier (BSA allo 0,1% di concentrazione finale) minimizza le perdite per adsorbimento. <\/p>\n<h2 id=\"faqs\">Domande frequenti<\/h2>\n<h3>What is HGH 191AA used for in studies?<\/h3>\n<p>HGH 191AA is used in studies investigating direct growth hormone receptor pharmacology, JAK2\/STAT5 signalling, hepatic IGF-1 induction, anabolic signalling in muscle and bone, hepatic metabolism, sleep-GH-axis relationships, GH-deficiency preclinical models, and comparative GH-axis pharmacology against GHRH analogs and growth hormone secretagogues. It is the canonical exogenous GH tool. The pharmaceutical-grade HGH 191AA sold here is <strong>not<\/strong> FDA-approved for non-clinical human use and is supplied strictly for clinical studies use only. <\/p>\n<h3>Qual \u00e8 la differenza tra HGH 191AA e 192AA?<\/h3>\n<p>The 191AA form is the modern pharmaceutical-quality recombinant human growth hormone matching the exact native human sequence (191 amino acids). The 192AA form was an older bacterial-recombinant variant with an additional N-terminal methionine residue (192 amino acids total) that was used in early pharmaceutical development before mammalian-cell expression systems became standard. The extra methionine produced minor antigenicity in some patient populations and the 192AA form has been largely phased out of both studies and clinical use. All pharmaceutical-grade HGH from MedsBase is the 191AA native-sequence form. <\/p>\n<h3>In cosa differisce HGH 191AA da Sermorelin?<\/h3>\n<p>HGH 191AA \u00e8 l'ormone della crescita esogeno stesso \u2014 il ligando attivo del recettore. <a href=\"https:\/\/medsbase.com\/it\/sermorelin\/\">Sermorelin<\/a> is a 29-amino-acid analog of GHRH (growth hormone releasing hormone) that stimulates the pituitary to release ENDOGENOUS GH. The downstream effects are similar in direction but qualitatively different: HGH produces tonic GHR exposure following each injection and bypasses pituitary feedback, while sermorelin produces a pulsatile GH release pattern and preserves natural somatostatin feedback regulation. Studies designs typically use one or the other depending on whether the question is about direct GHR pharmacology (HGH) or hypothalamic-pituitary-axis dynamics (sermorelin). <\/p>\n<h3>In cosa differisce HGH 191AA da IGF-1 LR3?<\/h3>\n<p>HGH 191AA agisce sul recettore dell'ormone della crescita, che stimola la produzione di IGF-1 da parte del fegato come principale effettore a valle. <a href=\"https:\/\/medsbase.com\/it\/igf-1-lr3\/\">IGF-1 LR3<\/a> bypasses this step and acts directly on the IGF-1 receptor. HGH studies the full GH\/IGF-1 axis including the upstream liver-mediated IGF-1 induction; IGF-1 LR3 isolates the IGF-receptor pharmacology and the direct downstream Akt\/mTOR anabolic signalling. Both compounds are frequently used in parallel arms of the same studies design to dissect direct GH effects from IGF-1-mediated effects. <\/p>\n<h3>What is the typical HGH 191AA dose?<\/h3>\n<p>Published preclinical studies dose ranges are typically 1\u20138\u00a0IU per administration in rodent and primate models, given subcutaneously once daily or pulsed to mimic endogenous secretion patterns. A 10\u00a0IU vial reconstituted with 1.0\u00a0mL bacteriostatic water yields 10\u00a0IU\/mL \u2014 0.1\u00a0mL equals 1\u00a0IU, 0.2\u00a0mL equals 2\u00a0IU. The conversion factor is approximately 3\u00a0IU per mg of recombinant 191AA HGH (WHO international standard). <\/p>\n<h3>HGH 191AA \u00e8 approvato dalla FDA?<\/h3>\n<p>Pharmaceutical recombinant 191AA HGH (somatropin) is FDA-approved under multiple brand names (Genotropin, Humatrope, Norditropin, Saizen, Omnitrope, Nutropin and others) for specific medical indications including paediatric growth hormone deficiency, adult GH deficiency, Turner syndrome, idiopathic short stature, AIDS-associated wasting, and short bowel syndrome \u2014 only under prescription and supervision by an endocrinologist. It is the most stringently regulated of all peptides in many jurisdictions. <\/p>\n<h3>Come dovrebbe essere conservato HGH 191AA?<\/h3>\n<p>Fiale liofilizzate: refrigerate a 2\u20138 \u00b0C per lo stock di lavoro a breve termine, o \u221220 \u00b0C per lo stoccaggio a lungo termine di fiale non aperte. Soluzione ricostituita: refrigerata a 2\u20138 \u00b0C, utilizzare entro 14 giorni (pi\u00f9 breve rispetto ai tipici piccoli peptidi perch\u00e9 il pi\u00f9 grande fascio a quattro eliche \u00e8 pi\u00f9 suscettibile all'adsorbimento superficiale e alla lenta deamidazione). Non congelare la soluzione ricostituita \u2014 i cicli di congelamento-scongelamento producono aggregazione e perdita di attivit\u00e0. Proteggere dalla luce diretta in ogni momento. <\/p>\n<h3>Come si ricostituisce l'HGH 191AA?<\/h3>\n<p>Seguire la procedura di ricostituzione sopra indicata. Aggiungere acqua batteriostatica lungo la parete laterale del flaconcino (non direttamente sulla polvere liofilizzata), agitare delicatamente e attendere 5\u201310 minuti per la completa dissoluzione. Non <strong>not<\/strong> agitare la fiala \u2014 un'agitazione vigorosa pu\u00f2 disturbare la struttura a quattro eliche e ridurre l'attivit\u00e0 biologica. Una soluzione correttamente ricostituita \u00e8 chiara e incolore, senza particelle visibili. <\/p>\n<h3>Quali dosaggi sono disponibili su MedsBase?<\/h3>\n<p>MedsBase carries HGH 191AA in 10\u00a0IU, 15\u00a0IU, 24\u00a0IU, 36\u00a0IU, and 40\u00a0IU lyophilized vials. Each strength is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at \u226598% HPLC purity with a certificate of analysis available on request. <\/p>\n<h3>Perch\u00e9 l'HGH \u00e8 misurato in IU piuttosto che in mg?<\/h3>\n<p>International Units (IU) are the standard measurement for biological-activity-based labelling of protein hormones, established by the WHO International Standard. For recombinant 191AA HGH, the conversion factor is approximately 3\u00a0IU per mg. The IU labelling convention is preferred because it directly references biological potency rather than mass, which is more reproducible across different recombinant production batches that may vary slightly in glycosylation state, deamidation profile, and folding-state heterogeneity. Both IU and mg are valid; the IU is the dominant unit in clinical and literature. <\/p>\n<h3>Perch\u00e9 la specifica di purezza \u00e8 del 98% piuttosto che del 99%?<\/h3>\n<p>Recombinant proteins like HGH cannot always achieve the \u226599% HPLC purity standard typical of small synthetic peptides because of inherent heterogeneity in any recombinant expression system \u2014 minor variants in folding state, deamidation isoforms, and other related species appear as related peaks on HPLC that are not impurities but isoforms of the target protein. \u226598% HPLC purity is a strong pharmaceutical-grade specification for recombinant 191AA HGH, intermediate between the 95% common for larger glycoproteins like <a href=\"https:\/\/medsbase.com\/it\/follistatin-344\/\">Follistatin 344<\/a> e il 99% comune per piccoli peptidi sintetici. <\/p>\n<h3>Does HGH 191AA cause side reported effects?<\/h3>\n<p>The principal on-target effects of HGH in study models are anabolic and metabolic: increased IGF-1 levels, increased lean body mass, decreased adiposity, transient insulin resistance, sodium and water retention, and increased mitogenic signalling. At supraphysiological exposures, off-target effects include carpal tunnel symptoms in primate models, glucose dysregulation, and (with chronic exposure) joint and soft-tissue overgrowth. The very strict regulatory framework around HGH for human use reflects these on-target risks at non-physiological doses. <\/p>\n<h3>Qual \u00e8 l'emivita dell'HGH 191AA?<\/h3>\n<p>In preclinical studies, recombinant HGH has a plasma half-life of approximately 3\u20135 hours following subcutaneous administration. The relatively short half-life reflects renal filtration (a 22-kDa protein is at the boundary of the glomerular filtration cutoff) and proteolytic clearance. Tissue half-life is longer because GHR-bound HGH persists at the cell surface for some time before internalisation. For protocols requiring sustained exposure, repeated daily dosing or specialised long-acting formulations would be needed; the standard recombinant 191AA form does not provide multi-day exposure from a single injection. <\/p>\n<h3>How long does HGH 191AA take to show effects in preclinical studies?<\/h3>\n<p>Gli effetti acuti sulla fosforilazione di JAK2\/STAT5 e sul programma di trascrizione immediatamente responsivo al GH sono rilevabili entro poche ore dalla somministrazione. L'induzione epatica di IGF-1 raggiunge il picco entro 24 ore. Gli effetti sulla composizione corporea (massa magra, massa adiposa) diventano tipicamente statisticamente significativi dopo 2\u20134 settimane di dosaggio regolare nei modelli roditori e continuano ad accumularsi fino a 8\u201312 settimane di somministrazione continua. <\/p>\n<h3>Posso ordinare HGH 191AA per la spedizione internazionale?<\/h3>\n<p>S\u00ec, dove consentito dalle normative locali. MedsBase spedisce HGH 191AA in tutto il mondo dalla nostra rete dedicata di spedizione di peptidi. Gli ordini contenenti solo peptidi si qualificano per il nostro servizio di spedizione peptidi autonomo. Tutti gli ordini vengono spediti in imballaggi a temperatura controllata con tracciamento completo e sono coperti dal nostro <a href=\"https:\/\/medsbase.com\/it\/medsbase-re-shipment-assurance-policy\/\">Politica di Garanzia di Rispedizione<\/a>. Note that HGH is the most stringently regulated peptide in many jurisdictions \u2014 please verify that local laws permit acquisition in your destination country before ordering. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Growth-Axis, GH-Release, and Anabolic Studies<\/h2>\n<ul>\n<li><a href=\"\/it\/sermorelin\/\"><strong>Sermorelin<\/strong><\/a> \u2014 Analogico GHRH(1-29) \u2014 stimola il rilascio endogeno di GH<\/li>\n<li><a href=\"\/it\/cjc-1295-with-dac\/\"><strong>CJC-1295 con DAC<\/strong><\/a> \u2014 Long-acting GHRH analog \u2014 canonical long-half-life GHRH use<\/li>\n<li><a href=\"\/it\/ipamorelin\/\"><strong>Ipamorelin<\/strong><\/a> \u2014 Segretagogo selettivo dell'ormone della crescita \u2014 pulso di GH pulito senza cortisolo\/prolattina<\/li>\n<li><a href=\"\/it\/igf-1-lr3\/\"><strong>IGF-1 LR3<\/strong><\/a> \u2014 Analogico ricombinante IGF-1 a lunga arginina \u2014 bypassa il passaggio del GH<\/li>\n<li><a href=\"\/it\/ghrp-6\/\"><strong>GHRP-6<\/strong><\/a> \u2014 First-generation hexapeptide GHS \u2014 ghrelin-axis GH release studies<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Approfondimenti<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Esplora l'asse dell'ormone della crescita<\/strong><\/p>\n<p style=\"margin: 0;\">Sfoglia l'intera <a href=\"https:\/\/medsbase.com\/it\/peptides\/\"><strong>catalogo peptidi<\/strong><\/a>, con composti correlati all'asse GH tra cui <a href=\"https:\/\/medsbase.com\/it\/sermorelin\/\">Sermorelin<\/a> e <a href=\"https:\/\/medsbase.com\/it\/cjc-1295-with-dac\/\">CJC-1295 con DAC<\/a> for endogenous-pulse studies, <a href=\"https:\/\/medsbase.com\/it\/ipamorelin\/\">Ipamorelin<\/a> for selective GHS studies, and <a href=\"https:\/\/medsbase.com\/it\/igf-1-lr3\/\">IGF-1 LR3<\/a> per il ramo a valle dell'asse IGF.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Ormone della crescita umano ricombinante a 191 aa (somatropina)<br \/>\n\u2705 Sequenza umana nativa \u2014 forma farmaceutica moderna di alta qualit\u00e0<br \/>\n\u2705 Agonista diretto del recettore GH (~22 kDa)<br \/>\n\u2705 Conversione standard ~3 UI per mg<br \/>\n\u2705 Purezza \u226598% HPLC, COA disponibile su richiesta<\/p>\n<p><strong>HGH 191AA<\/strong> \u00e8 una proteina ricombinante.<\/p>","protected":false},"featured_media":70958,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6288,5441],"class_list":["post-70770","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-hgh","product_tag-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/product\/70770","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/comments?post=70770"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/media\/70958"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/media?parent=70770"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/product_brand?post=70770"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/product_cat?post=70770"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/it\/wp-json\/wp\/v2\/product_tag?post=70770"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}